Vilajeliu, AlbaSequera Buzarquis, Victor GuillermoGarcía-Basteiro, Alberto L.Sicuri, ElisaAldea, MartaVelasco Muñoz, CésarBayas Rodríguez, José María2016-06-162016-06-162016-04-222164-5515https://hdl.handle.net/2445/99562Hepatitis B virus (HBV) vaccination is recommended for all susceptible chronic pre-hemodialysis and hemodialysis patients. This study assessed the immunogenicity of HBV vaccines (adjuvanted and non-adjuvanted) in chronic kidney disease patients vaccinated at the Hospital Clinic of Barcelona (Spain) between January 2007 and July 2012. In addition, the costs for the health system were evaluated according to the proportion of vaccine responders after receiving either vaccine. Patients receiving three doses of hepatitis B adjuvanted vaccine were three times more likely to seroconvert than patients immunized with non-adjuvanted vaccines, OR 3.56 (95% CI 1.84-6.85). This resulted in fewer patients requiring a second course of HBV vaccination and fewer outpatient visits, saving more than euro9,500 per 100 patients. The higher immunogenicity of the adjuvanted HBV vaccine would counterbalance the lower costs associated with the non-adjuvanted vaccine.18 p.application/pdfeng(c) Taylor & Francis, 2016Hepatitis BMalalties del ronyóHepatitis BKidney diseasesinfo:eu-repo/semantics/article2016-06-13info:eu-repo/semantics/openAccess27105182